Special Advisor to the Board
Neil K. Warma was appointed President and Chief Executive Officer of Opexa Therapeutics, Inc. in June 2008, and oversaw the successful sale and merger of Opexa with Acer Therapeutics in 2017. He has more than 25 years of executive level experience in the life sciences industry in the U.S., Europe and Canada. Prior to joining Opexa, Mr. Warma served as President & CEO and a member of the Board of Directors of Viron Therapeutics Inc., a privately-held clinical stage biopharmaceutical company developing a novel class of protein therapeutics. While at Viron, Mr. Warma positioned the company as a leader in the treatment of serious inflammatory disorders. Previously, Mr. Warma held several senior management positions at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland, in international policy and advocacy and in global marketing. In addition, Mr. Warma was co-founder and President of MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies, which was ultimately sold to a large public European firm. Mr. Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International M.B.A. from the Schulich School of Business at York University in Toronto. He currently serves on the Board of Directors of Orpheris, Inc. a biopharmaceutical company developing novel therapies for neurological diseases and is a member of the Board of Directors of BioHouston. He is also a Member of the Advisory Board for MD Anderson’s Institute of Applied Cancer Science.